Calidi Biotherapeutics(CLDI.US)

Last Updated 19:00:00 ET
longbridge loading
Company Encyclopedia
View More
name
Calidi Biotherapeutics
CLDI.US
Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, develops allogeneic stem cell-based and enveloped virus platforms to potentiate and deliver oncolytic viruses in the United States. Its product pipeline comprises CLD-101, which is in Phase 1b/2 clinical trial for the treatment of high-grade glioma, as well as in Phase 1 dose-escalation clinical trial for recurrent high-grade glioma; CLD-201 product for solid tumors, such as breast cancer, head and neck squamous cell carcinoma, and soft tissue sarcoma, which is in pre-clinical studies; CLD-301 for multiple indications, which is in preclinical studies; and CLD-400 for certain lung cancer and metastatic solid tumors. The company also offers oncolytic virus platforms, such as NeuroNova, SuperNova, and RTNova. Calidi Biotherapeutics, Inc.
1.970 T
CLDI.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    12 Health Care Stocks Moving In Tuesday's Pre-Market Session

    In Tuesday's pre-market session, several health care stocks experienced significant movements. Notable gainers included AlphaTON Capital (up 135.2% to $2.14), SciSparc (up 30.34% to $1.89), and enVVeno Medical (up 7.14% to $0.36). Conversely, Travere Therapeutics saw a sharp decline of 30.8% to $23.6, while China SXT Pharmaceuticals fell 12.58% to $0.12. Other notable losers included Intelligent Bio Solutions and Calidi Biotherapeutics, which dropped 8.2% and 8.02%, respectively.

    benzinga_article·
    US
    INBS
    -2.53%
    US
    TVTX
    +0.30%
    US
    CLDI
    -1.96%
    benzinga_article·
    US
    INBS
    -2.53%
    US
    TVTX
    +0.30%
    US
    CLDI
    -1.96%

    Chmn Camaisa Surrenders 850 Of Calidi Biotherapeutics Inc [CLDI]

    Camaisa Allan, Chairman of Calidi Biotherapeutics Inc, surrendered 850 shares back to the company to cover option exercise costs and/or tax liabilities, as disclosed in a Form 4 filed with the SEC on December 16, 2025. His ending holdings are 76,952 shares indirectly.

    Reuters·
    US
    CLDI
    -1.96%
    Reuters·
    US
    CLDI
    -1.96%

    Calidi Biotherapeutics and Nova Minerals Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

    RedChip Companies will air interviews with Calidi Biotherapeutics and Nova Minerals on Bloomberg TV. Calidi's CEO will discuss their RedTail platform for precision genetic medicine targeting tumors, while Nova's CEO will outline their Estelle Project in Alaska, focusing on gold and antimony production. Both companies aim to advance their respective projects, with Calidi targeting oncology markets and Nova aiming to become a tier-one gold producer and establish a U.S. antimony supply chain.

    Acceswire·
    US
    CLDI
    -1.96%
    Acceswire·
    US
    CLDI
    -1.96%

    Calidi Biotherapeutics Hosts Exclusive Investor Webinar Featuring CEO Eric Poma

    Calidi Biotherapeutics Inc. will host an investor webinar on November 19, 2025, featuring CEO Eric Poma. The event will cover insights into Calidi's RedTail platform, a viral therapy for delivering genetic medicines to tumors, and recent preclinical data. The information is provided by Public Technologies and originally published by Calidi Biotherapeutics via GlobeNewswire.

    Reuters·
    US
    CLDI
    -1.96%
    Reuters·
    US
    CLDI
    -1.96%

    Calidi Biotherapeutics Raises $6.9 Million in Offering

    Calidi Biotherapeutics raised $6.9 million through a public offering, despite a net loss of $5.2 million in Q3 2025. The company is advancing its RedTail platform and CLD-401 compound, aiming to enhance its position in virotherapy and genetic medicine delivery. Analysts rate CLDI stock as a Buy with a $2.50 target, though Spark's AI Analyst views it as Underperform due to financial and technical challenges. Calidi focuses on targeted therapies using its proprietary Redtail platform.

    Tip Ranks·
    US
    CLDI
    -1.96%
    Tip Ranks·
    US
    CLDI
    -1.96%
    © 2026 Longbridge｜Disclaimer